ARGX
argenx SECNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Primary company releases support a still-strong operating story: Q1 2026 product net sales reached $1.298 billion, up 63% year over year, and the May 2026 gMG label expansion plus positive ocular MG data extend the franchise runway [#IR-2026-05-07] [#PR-2026-05-08] [#PR-2026-02-26].
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
ALKIVIA, EMPASSION, and other pipeline readouts still carry binary clinical risk; supportive extension data do not remove registrational uncertainty.
Momentum
47
Value
59
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $920.00 · Bull $1,080.00 · Bear $720.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $1,066.75
Why
Momentum47 · Δ7d +4.2
Value59 · Δ7d +0.1
Sentiment50 · Δ7d +0.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
47
26% active weight
Current posture
7d trendSoftening
Δ7d
+4.2
Δ21d
-24.9
Value
59
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.1
Sentiment
50
34% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+3.6
Why this grade
Composite grade C. Momentum 46.5 / Value 59.3 / Sentiment 50.1
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$55.63B
Beta
0.72
Shares Out
62.56M
P/E (TTM)
34.6
P/S (TTM)
13.68
P/FCF (TTM) · Derived
69.82
Rev YoY
+96.6%
EPS YoY
+272.7%
Gross Margin
+88.7%
Op Margin
+21.9%
Net Debt
-$4.39B
Current Ratio
5.23
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology